|Videos|July 27, 2015
Mechanisms of Action for New Weight-Loss Agents
Advertisement
Episodes in this series
Jennifer L. Costello, PharmD, BCPS, BC-ADM, ambulatory care clinical pharmacist at Saint Barnabas Medical Center, reviews the pharmacologic mechanisms in the new weight-loss drugs.
Liraglutide, a glucagon-like peptide-1 receptor agonist, helps improve insulin secretion and reduce glucagon release. The drug dramatically affects patient satiation, so they eat less, Dr. Costello notes. It also causes some gastrointestinal upset, which can make some patients eat less.
Meanwhile, the naltrexone/bupropion combination affects central nervous system synapses by augmenting or modulating the craving zone—causing patients to have fewer food cravings.
Advertisement
Related to this article
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Convenience should not replace connection.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
2
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
3
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
4
Community Pharmacists Guide Patients New to Glucose Monitoring
5